Iwasaki, Takeshi
Watanabe, Ryu
Ito, Hiromu
Fujii, Takayuki
Ohmura, Koichiro
Yoshitomi, Hiroyuki
Murata, Koichi
Murakami, Kosaku
Onishi, Akira
Tanaka, Masao
Matsuda, Shuichi
Matsuda, Fumihiko
Morinobu, Akio
Hashimoto, Motomu
Article History
Received: 27 September 2023
Accepted: 13 December 2023
First Online: 2 January 2024
Declarations
:
: The present study was performed following the Helsinki Declaration and was approved by the Kyoto University Graduate School and Faculty of Medicine Ethics Committee (approval number: G0511). Written informed consent to participate in the present study and publish the results obtained was provided by all enrolled patients.
: Not applicable.
: Ryu Watanabe has received a research grant from AbbVie and speaker’s fee from Asahi Kasei, Chugai, Eli Lilly, and GSK. Hiromu Ito received Grant/research support from Bristol Myers. Takayuki Fujii received Speakers bureau from Asahi Kasei Pharma, Abbvie, Jansen, Tanabe Mitsubishi Pharma, and Eisai Co LTD. Koichi Murata received speakers bureau from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd., and Asahi Kasei Pharma Corp., Grant/research support from: Daiichi Sankyo Co. Ltd. Kosaku Murakami received speakers bureau from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., Astellas Pharma Inc., UCB Japan Co. and Asahi Kasei Pharma Corp. Akira Onishi received Speakers bureau: Pfizer Inc., Bristol-Myers Squibb., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., Abbvie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd., Grant/research support from: Pfizer Inc., Bristol-Myers Squibb., Advantest, Ayumi, and the Health Care Science Institute., Employee of: Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan, and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). It is also supported by grants from Daiichi Sankyo Co. Ltd. Above-mentioned pharmaceutical companies were not involved in the study design, data collection and analysis, manuscript writing, and manuscript submission. Masao Tanaka received speakers bureau from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Tanabe Mitsubishi Pharma Corp., UCB Japan Co., Ltd., Grant/research support from: AbbVie GK, Kyowa Kirin Co., Ltd. Taisho Pharmaceutical Co., Ltd. Teijin Pharma, Ltd, Employee of: M.T. belongs to the department financially supported by two local governments in Japan (Nagahama City, Shiga and Toyooka City, Hyogo) and two pharmaceutical companies (Ayumi Pharmaceutical Corp., Asahi Kasei Pharma Corp.)., Akio Morinobu received speakers bureau from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., and Gilead Sciences Japan., Grant/research support from: AbbVie G.K., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co. Taisho Pharmaceutical Co., Ltd.,and Eisai Co. Ltd. outside the work., Motomu Hashimoto received speakers bureau from Eli Lilly, Chugai, Mitsubishi Tanabe, Bristol Myers, Eisai, Grant/research support from: AbbVie, Asahi Kasei, Astellas, Bristol Myers, Eisai, Daiichi Sankyo, Eli Lilly, Novartis, Eisai, Taisho Toyama. No other author declares a competing interest.